Analysis: Industry-Funded Honeybee Study Was “Misleading”

Statisticians debunk a 2013 study by scientists at a Swiss agrochemical company, which had reported that a neonicotinoid pesticide posed a low risk to honeybees.

Written byJoshua A. Krisch
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, JOHN SEVERNSScientists are scrambling to protect honeybees and bumblebees as climate change, disease, and pesticides chip away at their fragile populations. Several studies have implicated neonictinoid pesticides in the deaths of honeybees and other pollinators. But proponents of these compounds point to a 2013 PLOS ONE study by researchers at the Swiss agrochemical company Syngenta, which reported that neonictinoida pose low risk to bee populations.

But now, as described in a study published January 23 in Environmental Sciences Europe, another group has analyzed the statistical methods behind the Syngenta-led study, finding them wanting. “The estimates of the treatment effects were so imprecise that one could not tell whether the effects were either too small to pose a problem or, in contrast, so large as to be of serious concern,” coauthor Jeremy Greenwood of the University of St Andrews in Scotland said in a statement. “The experiments were on such a small scale that little useful could be concluded from them.”

The statistical re-analysis comes on the heels of revelations that Syngenta had been hiding unpublished research—obtained by Greenpeace through the US Freedom of Information Act—indicating that high doses of the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies